Shots:
- J&J has reported P-III (ASTRO) trial data assessing Tremfya SC induction (400mg at Wks. 0, 4 & 8) followed by either Tremfya 100mg SC Q8W or 200mg SC Q4W vs PBO in adults with mod. to sev. active UC; sBLA under the US FDA’s review
- At Wk. 24, trial showed improved clinical remission rates of 35.3% (100mg) & 36.4% (200mg) vs 9.4%, with superior symptomatic remission (54.7% & 50.0% vs 25.2%) & endoscopic improvement (40.3% & 45% vs 12.2%); clinical response was 63.3% & 61.4% vs 30.9%
- Subgroup analyses showed significant benefits across EPs in both biologic & JAK inhibitor-naïve & refractory pts at 24wks.; data was presented at DDW 2025
Ref: Johnson & Johnson | Image: Johnson & Johnson
Related News:- Johnson & Johnson’s Tremfya Receives the EC’s Approval for Active Ulcerative Colitis (UC)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click Here for Full Press Release
